Medicus Pharma Files EU CTIS Submission to Advance Teverelix Phase 2b Registrational Study

Medicus Pharma's EU Clinical Trials Information System (CTIS) substantial modification submission signals a concrete step toward registrational development for Teverelix® in advanced prostate cancer, placing the program squarely within Europe's centralised clinical trial oversight framework ahead of a planned 2026 Phase 2b initiation.

The submission targets a patient segment that existing hormonal therapies have not formally addressed: men with elevated cardiovascular risk requiring androgen deprivation therapy (ADT). Published data cited by the company indicate that between 20% and 60% of advanced prostate cancer patients carry underlying cardiovascular disease, and approximately 30% of those requiring ADT present with elevated cardiovascular risk. No approved hormonal therapy currently holds a regulatory label specific to this population, a gap that shapes the clinical and regulatory rationale for the Teverelix® program.

Teverelix® is a long-acting GnRH antagonist formulated as a depot injection. Its proposed differentiation from conventional GnRH agonists rests on flare-free rapid testosterone suppression and pronounced follicle-stimulating hormone suppression, characteristics the company believes are clinically relevant where cardiovascular outcomes are a primary concern. The planned Phase 2b study is designed to optimise dose selection and characterise the pharmacokinetic, pharmacodynamic, efficacy, and safety profile required to support subsequent registrational planning.

For regulatory affairs leads tracking the CTIS pathway, the submission category matters: a substantial modification application under EU Clinical Trials Regulation 536/2014 requires coordinated assessment across member states and carries defined review timelines that differ from the legacy national competent authority routes. Companies advancing oncology assets toward registrational development in Europe are increasingly stress-testing CTIS workflows, and Medicus's filing adds a live data point to that operational picture.

Medicus has previously engaged with the U.S. Food and Drug Administration on its advanced prostate cancer development strategy, including studies focused on high cardiovascular-risk patients, indicating a parallel regulatory dialogue that could inform protocol alignment between the EU and U.S. registrational paths. The company estimates the addressable population represents approximately $4 billion in annual market opportunity across major pharmaceutical markets.

Completion of the Phase 2b study and the data package it generates will determine whether Teverelix® can support a prospective cardiovascular-risk label claim, the regulatory threshold that would distinguish it from currently approved GnRH antagonists.

Source: Medicus Pharma Ltd. via GlobeNewswire, 8 June 2026.